The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: A randomized, controlled clinical trial

British Journal of Dermatology

Volumn 160, Issue 2, 2009, Pages 415-422

  Hoeger, P H ^a   Lee, K H ^b   Jautova, J ^c   Wohlrab, J ^d   Guettner, A ^e   Mizutani, G ^e   Hultsch, T ^e  

^a Catholic Children's Hospital Wilhelmstift   (Germany)

^b Yonsei University College of Medicine   (South Korea)

^c Fakultna Nemocnica L Pasteura   (Slovakia)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Facial atopic dermatitis; Pimecrolimus; Randomized controlled trial; Topical corticosteroids

Indexed keywords

CORTICOSTEROID; DRUG VEHICLE; PIMECROLIMUS;

APPLICATION SITE ERYTHEMA; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; BRONCHITIS; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FACIAL ATOPIC DERMATITIS; FEVER; GASTROENTERITIS; HERPES SIMPLEX; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OTITIS MEDIA; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SCHOOL CHILD; SCORING SYSTEM; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ECZEMA; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; PRURITUS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; VEHICLES;

EID: 58349092742     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08928.x     Document Type: Article

References (31)

1. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994 30 : 35 9.
2. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003 112 (Suppl. 6 S118 27.
3. Schultz-Larsen F, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002 22 : 1 24.
4. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 60.
5. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996 35 : 615 19.
6. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol 1979 18 : 23 31.
7. Rapaport MJ, Lebwohl M. Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome. Clin Dermatol 2003 21 : 201 14.
8. Hengge UR, Ruzicka T, Schwarz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006 54 : 1 15.
9. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001 20 : 233 41.
10. Allen BR, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 88 : 969 73.
11. ®, SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002 204 : 63 8.
12. Lakhanpaul M, Davies T, Allen BR, Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year study with pimecrolimus cream 1%. Exp Dermatol 2006 15 : 138 41.
13. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 144 : 507 13.
14. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 46 : 495 504.
15. Zuberbier T, Bräutigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008 22 : 718 21.
16. Hanifin JM, Thurston M, Omoto M et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001 10 : 11 18.
17. Barbier N, Paul C, Luger T et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004 150 : 96 102.
18. Hanifin J, Rajka G. Diagnostic criteria for atopic dermatitis. Acta Derm Venereol (Stockh) 1980 92 (Suppl. 44 7.
19. Freeman AK, Serle J, van Veldhuisen P et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004 73 : 267 71.
20. Murrell DF, Calvieri S, Ortonne JP et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007 157 : 954 9.
21. Ho VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003 142 : 155 62.
22. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006 144 : 1 9.
23. Biedermann T. Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol (Stockh) 2006 86 : 99 109.
24. Roll A, Cozzio A, Fischer B, Schmid-Grendelmeier P. Microbial colonization and atopic dermatitis. Curr Opin Allergy Clin Immunol 2004 4 : 373 8.
25. Sahni D, Darley CR, Hawk JL. Glaucoma induced by periorbital topical steroid use - a rare complication. Clin Exp Dermatol 2004 29 : 617 19.
26. thoe Schwartzenberg GW, Buys YM. Glaucoma secondary to topical use of steroid cream. Can J Ophthalmol 1999 34 : 222 5.
27. Cork MJ, Robinson DA, Vasilopoulos Y et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006 118 : 3 21.
28. Palmer C, Irvine D, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006 38 : 441 6.
29. Lee H, Hwang K. Skin thickness of Korean adults. Surg Radiol Anat 2002 24 : 183 9.
30. Sheu HM, Lee JYY, Chai CY, Kuo KW. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997 136 : 884 90.
31. Cork MJ, Varghese J, Hadcraft J et al. Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - implications for therapy. J Invest Dermatol 2006 127 : S45.